Accessibility Menu
Achieve Life Sciences logo

Achieve Life Sciences(NASDAQ) ACHV

Market Cap$659.07MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-99%
5 Year-12%
1 Year+146%
1 Month+0%
$6.42
+1.91%
+0.12Today
After hours$6.40-$0.02 (-0.39%)
Achieve Life Sciences last closing stock price
MetricPriceDate
Last closeUSD 6.422026-07-31
Achieve Life Sciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+5.25%USD 6.102026-07-24
1 month+0.31%USD 6.402026-07-01
3 month+46.58%USD 4.382026-05-01
Year to date+29.18%USD 4.972025-12-31
1 year+145.98%USD 2.612025-07-31
3 year+14.03%USD 5.632023-08-01
5 year-12.18%USD 7.312021-07-30
Since inception-99.28%USD 880.092017-08-02

Achieve Life Sciences Financials at a Glance

Market Cap

$659.07MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$51.99M

EPS (TTM)

-$1.12

P/E Ratio

-5.76

Dividend

$0.00

Beta (Volatility)

1.02 (Average)

Price

$6.42

Volume

1,181,779.877

Open

$6.30

Previous Close

$6.42

Daily Range

$6.05 - $6.46

52-Week Range

$2.37 - $7.11

Estimated Earnings Date

Aug 6, 2026

ACHV News

Foolcom-Featured.png

Achieve (ACHV) Q2 Net Loss Hits $12.7M

Motley Fool Markets TeamAug 7, 2025

ACHV: Motley Fool Moneyball Superscore

52

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Achieve Life Sciences

Achieve helps people quit smoking and nicotine by developing new medicines. Its main product aims to reduce withdrawal symptoms for smokers and vapers. The company focuses on those struggling to stop nicotine use.

Products and Services

  • Cytisinicline: A plant-based medicine candidate for quitting smoking and nicotine, targeting adults who want to stop cigarettes or e-cigarettes.
  • Clinical Trials: Runs studies in the United States to test cytisinicline’s safety and effectiveness for smokers and vapers.
  • Licensing Agreements: Holds exclusive rights to cytisinicline outside Central and Eastern Europe, partnering with pharmaceutical companies and universities.
  • Manufacturing Partnerships: Works with U.S.-based manufacturers to prepare for commercial production if approved.

Growth and Expansion

  • Signed exclusive supply agreement with Sopharma AD for cytisinicline in 2015.
  • Secured licensing deal with University of Bristol for technology rights in 2016.
  • Partnered with Adare Pharma Solutions in 2025 for U.S. manufacturing.
  • Expanded clinical trials to include vaping cessation in 2022.

What Makes Achieve Stand Out

Achieve focuses on a single, plant-based therapy for nicotine addiction. It targets both traditional smokers and e-cigarette users, a growing market. The company’s U.S. manufacturing partnerships aim to reduce supply risks and costs.

Five Things You Need to Know

  • No revenue recognized in QQ3 2023, QQ3 2024, or QQ3 2025.
  • Net loss was $54.6 million in 2025, up from $39.8 million in 2024.
  • Cash and marketable securities were $36.4 million at December 31, 2025.
  • Operating expenses fell 17.9% year-over-year to $15 million in QQ3 2025.
  • Company faces substantial doubt about continuing operations without new funding.

Bottom Line

Achieve is a small biotech focused on one smoking cessation drug. Its future depends on regulatory approval and securing more capital.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

28

CEO

Richard Alistair Balfour Stewart

Website

www.achievelifesciences.com

Headquarters

Bothell, WA 98021, US

ACHV Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-193.49%

Return on Capital

-150.47%

Return on Assets

-157.04%

Earnings Yield

-17.36%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$659.07MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

102.66M

Volume

1.18M

Avg. Volume

1.80M

Financials (TTM)

Gross Profit

-$111.00K

Operating Income

-$52.45M

EBITDA

-$50.86M

Operating Cash Flow

-$45.31M

Capital Expenditure

-$3.00K

Free Cash Flow

-$45.31M

Cash & ST Invst.

$29.27M

Total Debt

$14.95M

Achieve Life Sciences Performance Analysis

Achieve Life Sciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Achieve Life Sciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Achieve Life Sciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -4.00-2.1%
20232023-12-31USD -1.50-62.4%
20242024-12-31USD -1.24-17.4%
20252025-12-31USD -1.251.0%
Achieve Life Sciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-3024.3%
Q42025-12-31N/A
Q12026-03-3132.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$57.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$659.07MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$23.54M

N/A

Employees

28

N/A

Net Income

-$10.17M

+20.7%

EBITDA

-$9.84M

+21.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$29.27M

+25.9%

Total Debt

$14.95M

+50.1%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$9.32M

+7.0%

Short Term Debt

$5.63M

+350.0%

Return on Assets

-1.57%

N/A

Return on Invested Capital

-2.47%

N/A

Free Cash Flow

-$6.93M

+37.5%

Operating Cash Flow

-$6.93M

+37.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ALLOAllogene Therapeutics, Inc.
$1.88-4.57%
AVIRAtea Pharmaceuticals, Inc.
$4.70-0.84%
VNDAVanda Pharmaceuticals Inc.
$5.10-1.54%
TRDAEntrada Therapeutics, Inc.
$6.79+0.30%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About ACHV

What is the current price of Achieve Life Sciences?

Achieve Life Sciences is trading at $6.42 per share.

What is the 52-week range for Achieve Life Sciences?

Over the past 52 weeks, Achieve Life Sciences has traded between $2.37 and $7.11.

How much debt does Achieve Life Sciences have?

As of the most recent reporting period, Achieve Life Sciences reported total debt of $14.95M.

How much cash does Achieve Life Sciences have on hand?

Achieve Life Sciences reported $28.08M in cash and cash equivalents in its most recent financial results.

What is Achieve Life Sciences’s dividend yield?

Achieve Life Sciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services